• Home  
  • FDA Approves Novo’s Sogroya for Children with Turner Syndrome
- News

FDA Approves Novo’s Sogroya for Children with Turner Syndrome

The approval allows children aged 2.5 years and older with Turner syndrome to receive once-weekly growth hormone treatment, offering an alternative to daily injections.

Novo’s Once-Weekly Growth Hormone Sogroya Gets FDA Nod for Children with Turner Syndrome

The US Food and Drug Administration (FDA) has approved Novo Nordisk’s once-weekly Sogroya (somapacitan-beco) injection (5 mg, 10 mg or 15 mg) for children aged 2.5 years and older with growth failure associated with Turner syndrome (TS), a chromosomal condition that affects development in females and commonly causes short stature.

With this approval, Sogroya is now indicated in the US for five distinct growth-related conditions in children.

Sogroya is a long-acting growth hormone also approved in the US for children aged 2.5 years and older with idiopathic short stature (ISS); short stature in children born small for gestational age (SGA) who have not demonstrated catch-up growth by the age of two; growth failure associated with Noonan syndrome (NS); and growth failure due to inadequate secretion of endogenous growth hormone. It is also indicated for adults with growth hormone deficiency (GHD).

“For children with Turner Syndrome, growth hormone treatment can be part of everyday life for years. How they experience that treatment matters,” said Colleen Silk, group vice president, Rare Disease, Novo.

“A once-weekly option represents a meaningful advancement in how we support growth in children with Turner Syndrome, reducing the number of injections throughout that journey,” Silk added.

The approval was based on the results of the pivotal REAL8 study, which showed that children aged 2.5 years and older with TS who received once-weekly Sogroyagrew at a comparable rate over 52 weeks as those who received daily growth hormone.  

“Daily growth hormone therapy works well, but staying consistent with treatment over time can be difficult — especially in conditions like Turner Syndrome, where families may struggle with managing multiple comorbidities and medications,” said Dr Aristides Maniatis, founder of Rocky Mountain Endocrinology and an investigator in the REAL8 trial.

“By offering a once-weekly treatment option, Sogroya provides 313 injection-free days each year. This weekly alternative to daily therapy may help make the growth hormone routine simpler to fit into the lives of children and their caregivers,” he added.

Turner syndrome is a chromosomal condition that affects development in females. It occurs when one of the two X chromosomes is missing or partially altered. The condition most commonly causes short stature and fertility problems. Individuals with Turner syndrome may also have congenital heart defects and kidney problems.

According to data cited by Novo, the condition occurs in approximately one in 2,000 female newborns.

About Us

HealthXplore is a digital platform dedicated to delivering insights into what’s new and what’s next in healthcare, pharmaceuticals, and medical innovation. We aim to bridge the gap between complex industry developments and informed audiences by presenting credible, timely, and engaging content.

Contact: +91 9354115542

HealthXploreIndia @2026. All Rights Reserved.